Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed/Refractory Acute Leukemia or High-Risk MDS | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02543879

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed/Refractory Acute Leukemia or High-Risk MDS
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 
This is an open-label, multicenter, dose-escalation Phase 1 study in patients with acute leukemia or high-risk MDS, intended to investigate safety, pharmacokinetics, and the pharmacodynamic effects of FT-1101 administered via one or more intermittent dosing schedules. Once the MTD has been established, up to 42 additional patients may be enrolled in 3 expansion cohorts in selected patient populations at the recommended dose for future studies to confirm safety.
Status: 
Recruiting
Study Date: 
Tue, 09/01/2015 to Thu, 02/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: FT-1101 FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level Other Name: FT1101